Zai Lab (NASDAQ:ZLAB) Insider Sells $196,029.46 in Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) insider Joshua Smiley sold 9,614 shares of the stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $20.39, for a total transaction of $196,029.46. Following the completion of the sale, the insider directly owned 120,619 shares of the company’s stock, valued at $2,459,421.41. This trade represents a 7.38% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Zai Lab Stock Performance

NASDAQ ZLAB remained flat at $20.41 during mid-day trading on Friday. The company’s stock had a trading volume of 707,427 shares, compared to its average volume of 746,471. The firm’s fifty day simple moving average is $18.63 and its two-hundred day simple moving average is $21.91. The stock has a market capitalization of $2.30 billion, a P/E ratio of -12.68 and a beta of 0.86. Zai Lab Limited Unsponsored ADR has a 12-month low of $15.96 and a 12-month high of $44.34.

Zai Lab (NASDAQ:ZLAB) last announced its quarterly earnings data on Saturday, February 14th. The company reported ($0.50) earnings per share (EPS) for the quarter. Zai Lab had a negative net margin of 38.15% and a negative return on equity of 22.81%. The firm had revenue of $127.60 million for the quarter. Equities analysts expect that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current year.

Hedge Funds Weigh In On Zai Lab

An institutional investor recently raised its position in Zai Lab stock. SG Americas Securities LLC grew its stake in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 6.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,396 shares of the company’s stock after acquiring an additional 642 shares during the period. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 41.65% of the company’s stock.

Analyst Upgrades and Downgrades

ZLAB has been the topic of a number of research analyst reports. Cantor Fitzgerald lowered their target price on Zai Lab from $55.00 to $37.00 and set an “overweight” rating on the stock in a report on Friday, February 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zai Lab in a research report on Wednesday, January 21st. Zacks Research downgraded shares of Zai Lab from a “hold” rating to a “strong sell” rating in a research report on Friday, January 23rd. UBS Group began coverage on Zai Lab in a research note on Wednesday, January 7th. They set a “buy” rating and a $35.00 price target for the company. Finally, Jefferies Financial Group raised shares of Zai Lab to a “strong-buy” rating in a research report on Monday, January 19th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Zai Lab presently has an average rating of “Moderate Buy” and a consensus target price of $50.00.

About Zai Lab

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.